What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? (JAZ-TOP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01692977 |
Recruitment Status :
Completed
First Posted : September 26, 2012
Last Update Posted : July 30, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer Disease | Other: neuropsychological assessment | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 77 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Orienting Oneself in a Healing Garden: What Elements of the Design Are Used as Landmarks by Patients With Alzheimer's Disease ? |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Alzheimer disease patients
Alzheimer disease patients
|
Other: neuropsychological assessment |
Active Comparator: control
healthy control subjects.
|
Other: neuropsychological assessment |
- Analyze nature and frequency of elements of the " art, memory and life " garden used as landmarks by Alzheimer's disease patients [ Time Frame: Baseline = inclusion visit ]To describe and compare nature and frequency of elements involved in orientation decisions and the cognitive map, between a group of subjects with Alzheimer's disease and a group of healthy control subjects.
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects. [ Time Frame: Baseline = inclusion visit ]To identify, through analysis of interviews based on problem solving and interlocutory logic (TROGNON and BATT, 2007,2010, 2011), the characteristics of the elements of the " art, memory and life " garden that contributed to decision-making regarding spatial orientation and the development of a mental representation of the garden, in patients with Alzheimer's disease and healthy elderly subjects.
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects. [ Time Frame: Baseline = inclusion visit ]To study the correlation between the degree of success in experimental tasks (route learning, cognitive map) and standard and specific neuropsychological assessment (visuospatial skills) of individuals with Alzheimer's disease and healthy control subjects.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 90 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
All subjects (groups A and B):
- able to walk autonomously, that is without help, whether human or technical, except for a walking cane
- are aged 65 to 90 years
- have never been in the "art, memory and life" garden at the Paul SPILLMANN Centre prior to the study
- have given their written consent after receiving clear and intelligible oral and written information.
Group A : patients with Alzheimer's disease:
- diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA diagnostic criteria (Mc KHANN et al., 1984)
- score less than or equal to 4 on the Hachinski ischemic scale (Hachinski et al., 1984)
- Folstein MMSE score between 10 and 24 inclusively
- score equal to 5 or 6 on the Reisberg Global Deterioration Scale (REISBERG et al., 1982).
- stable, specific treatment of Alzheimer's disease (cholinesterase and memantine)
- taking of psychotropic drugs authorized, but no change in treatment during at least the last 48 hours
Group B: healthy control subjects:
- absence of dementia according to NINCDS-ADRDA criteria (Mc KHANN et al., 1984)
- normal performance on Folstein MMSE, according to the GRECO (en français : Groupe de REflexions sur les Evaluations Cognitives) standards (Reflection Group on Cognitive Assessments)
Exclusion Criteria:
For all subjects (groups A and B):
- Absence of social security coverage
- sensory deficit interfering with the task
- aphasia interfering with the task
- history of head trauma (with loss of consciousness)
- chronic alcoholism
- refusal or inability to obtain written informed consent form from the patient
- legally protected person
- severe depression: score higher than 20 on the 30-item Geriatric Depression Scale (GDS)
Group A : patients with Alzheimer's disease:
- other neurological or psychiatric diseases that may affect the assessment Group B: healthy control subjects
- neurological or psychiatric diseases that may affect the assessment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01692977
France | |
University Hospital of Nancy , Saint Julien Hospital, France | |
Nancy, France, 54000 |
Principal Investigator: | Thérèse Rivasseau Jonveaux, PhD | University Hospital of Nancy, France |
Responsible Party: | Central Hospital, Nancy, France |
ClinicalTrials.gov Identifier: | NCT01692977 |
Other Study ID Numbers: |
2011-A00993-38 |
First Posted: | September 26, 2012 Key Record Dates |
Last Update Posted: | July 30, 2015 |
Last Verified: | July 2015 |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |